Clinical Trials on GHD in South Africa

Total 16 results

Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
Monash University
Novartis Pharmaceuticals

Recruiting

VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) (v-ASCERTAIN)

Cerebrovascular Disease | Coronary Heart Disease (CHD) | Peripheral Arterial Disease (PAD) | Atherosclerotic Cardiovascular Disease (ASCVD)

Australia
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Completed

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Chronic GVHD

United States
Rambam Health Care Campus
Hadassah Medical Organization; Tel-Aviv Sourasky Medical Center; Soroka University...

Completed

α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD (AATGVHD-MARK)

GVHD | Bone Marrow Transplant Failure | Alpha 1-Antitrypsin

Israel
CardioDx

Withdrawn

Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making (CU-PCP)

Cardiovascular Diseases | Coronary Artery Disease | Chest Pain | Angina Pectoris | Coronary Heart Disease | CAD | CHD | CVD

United States
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Shire

Completed

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Phobia, Social | Anxiety, Separation | Generalized Anxiety Disorder (GAD)

United States
Carl Backes, MD
Children's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Cord Clamping Among Neonates With Congenital Heart Disease (CORD-CHD)

Congenital Heart Disease (CHD)

United States, Canada
Incyte Corporation

Completed

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Graft-versus-host Disease (GVHD)

United States, Spain, Belgium, France, Italy, Korea, Republic of, Finland, United Kingdom, Germany, Israel, Switzerland, Austria, Australia, Czechia, Greece, New Zealand, Poland, Portugal, Taiwan
AstraZeneca
Thrombolysis in Myocardial Infarction (TIMI) Study Group

Completed

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction (GOLDILOX)

Coronary Heart Disease (CHD)

United States, Italy, Netherlands, Spain, Japan, Czechia, Hungary, Australia, Poland, Canada, United Kingdom
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
Amgen

Active, not recruiting

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Coronary Heart Disease (CHD)

Canada, France, United States, Spain, United Kingdom, Korea, Republic of, Netherlands, Austria, Australia, Czechia, Taiwan, Finland, Hungary, Italy, Poland, Greece, Germany, Brazil, Latvia, Denmark, Mexico, Russian Federation, Bulgaria and more
Neovii Biotech

Completed

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Myelodysplastic Syndrome | GVHD | Adult Acute Myeloid Leukemia | Adult Acute Lymphoid Leukemia

United States, Australia
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia
Genzyme, a Sanofi Company

Approved for marketing

Alglucosidase Alfa Temporary Access Program (ATAP)

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia

Clinical Trials on GHD in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations